Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas
MC Chamberlain - Expert review of neurotherapeutics, 2010 - Taylor & Francis
Temozolomide-based chemotherapy represents an incremental improvement in the
treatment of patients with high-grade gliomas. Notwithstanding a survival benefit in a subset …
treatment of patients with high-grade gliomas. Notwithstanding a survival benefit in a subset …
Temozolomide in malignant glioma
G Dresemann - OncoTargets and therapy, 2010 - Taylor & Francis
Glioblastoma multiforme WHO grade IV (GBM) is the most aggressive malignant glioma and
the most frequent primary tumor of the central nervous system. The median survival of newly …
the most frequent primary tumor of the central nervous system. The median survival of newly …
Phase II trial of temozolomide in patients with progressive low-grade glioma
JA Quinn, DA Reardon, AH Friedman… - Journal of clinical …, 2003 - ascopubs.org
Purpose: Temozolomide (Temodar; Schering-Plough Corp, Kenilworth, NJ) is an imidazole
tetrazinone that undergoes chemical conversion to the active methylating agent 5-(3 …
tetrazinone that undergoes chemical conversion to the active methylating agent 5-(3 …
Temozolomide in malignant gliomas: current use and future targets
JL Villano, TE Seery, LR Bressler - Cancer chemotherapy and …, 2009 - Springer
Temozolomide (TMZ) is an oral alkylating agent that is regarded as a tolerable and effective
drug. When combined with radiotherapy in patients with newly diagnosed glioblastoma …
drug. When combined with radiotherapy in patients with newly diagnosed glioblastoma …
Temozolomide for recurrent high-grade glioma
DR Macdonald - Seminars in oncology, 2001 - Elsevier
Despite aggressive treatment, the high-grade malignant glioma (specifically, anaplastic
astrocytoma and glioblastoma multiforme) have a poor prognosis with current methods …
astrocytoma and glioblastoma multiforme) have a poor prognosis with current methods …
Evidence-based practice: temozolomide beyond glioblastoma
J Chua, E Nafziger, D Leung - Current oncology reports, 2019 - Springer
Abstract Purpose of Review Temozolomide is a first-line treatment for newly diagnosed
glioblastoma. In this review, we will examine the use of temozolomide in other contexts for …
glioblastoma. In this review, we will examine the use of temozolomide in other contexts for …
[HTML][HTML] Extended-schedule dose-dense temozolomide in refractory gliomas
A Berrocal, P Perez Segura, M Gil, C Balaña… - Journal of Neuro …, 2010 - Springer
This multicenter phase II study conducted by the Spanish Neuro-Oncology Group evaluated
the activity of an extended, dose-dense temozolomide regimen in patients with …
the activity of an extended, dose-dense temozolomide regimen in patients with …
Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas
Protracted low dose temozolomide (75 mg/m 2/day on days 1–21 of 28 days) offers potential
advantages over standard temozolomide schedules (200 mg/m 2/day on days 1–5 of 28 …
advantages over standard temozolomide schedules (200 mg/m 2/day on days 1–5 of 28 …
[HTML][HTML] Temozolomide with radiation therapy in high grade brain gliomas: pharmaceuticals considerations and efficacy; a review article
GV Koukourakis, V Kouloulias, G Zacharias… - Molecules, 2009 - mdpi.com
Malignant gliomas (glioblastoma multiforme and anaplastic astrocytoma) which have a
combined incidence of 5–8/100,000 population, represent the most common primary central …
combined incidence of 5–8/100,000 population, represent the most common primary central …
Temozolomide in malignant gliomas.
WK Yung - Seminars in oncology, 2000 - europepmc.org
Glioblastoma multiforme and anaplastic astrocytoma are the most common primary central
nervous system malignancies and are the major cause of morbidity/mortality despite …
nervous system malignancies and are the major cause of morbidity/mortality despite …